Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Biogen Inc. said Wednesday it’s acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at bolstering its immunology portfolio.
Biogen Inc. said Wednesday it’s acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at bolstering its immunology portfolio.
